BEIJING: China National Biotec Group (CNBG) said on Sunday that early human test results for a coronavirus vaccine candidate suggested it might be safe and effective, the second vaccine candidate from the firm to point out encouraging leads to a clinical test .
The experimental shot, developed by a Beijing-based unit of CNBG, has induced high-level antibodies altogether the inoculated participants during a Phase 1/2 clinical test involving 1,120 healthy people, consistent with preliminary data of the trial, CNBG said during a posting on the social media platform WeChat, without disclosing specific readings.
Chinese companies and researchers are allowed to check eight vaccine candidates in humans reception and abroad, making China a serious front-runner within the race to develop an attempt against the virus that has killed nearly 500,000 people globally.
CNBG, affiliated to the state-owned China National Pharmaceutical Group (Sinopharm), said earlier this month that another vaccine candidate produced by its Wuhan-based unit also triggered high-level antibodies safely in clinical test participants supported preliminary results.
A vaccine has got to prove its effectiveness in “Phase 3” human test where thousands of participants are recruited so as to be cleared purchasable .
CNBG said on Tuesday it’ll run a Phase 3 for its vaccine candidate within the United Arab Emirates, without specifying which shot are going to be tested.